AstraZeneca (NYSE: AZN) announced that the FDA has approved Bydureon (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback